CSL Behring gains expanded use for Corifact in USA

Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII (FXIII) deficiency.  The drug is market by CSL Behring, a unit of Australia’s CSL Limited (ASX: CSL).

More than two years ago, the FDA approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency (The Pharma Letter February 18, 2011).

Congenital FXIII deficiency is a rare and potentially life-threatening bleeding disorder in which blood clots normally, but the clots formed are unstable, leading to recurrent bleeding. It is estimated that the condition affects one person in two million, with prevalence in the U.S. of approximately 150 people.